Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 22,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Active, not recruiting Phase 4 Interventional

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

NCT05127109
View directory record Official record
Conditions
Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions
Nutrition Ecosystem pathway, Comparator
Combination Product · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational

Ten-year Outcomes After AF Ablation

NCT01867099
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Valley Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

NCT03960463
View directory record Official record
Conditions
Surgical Wound, Diabetes, Amputation Wound, Incision Wound, Peripheral Arterial Disease, Breast Cancer, Diabetic Foot
Interventions
Transcu O2®
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers

NCT04076995
View directory record Official record
Conditions
Dehydration, Diabetes Mellitus, Type 2
Interventions
Water Intake
Other
Lead sponsor
Arizona State University
Other
Eligibility
30 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

Micra Transcatheter Pacing System Continued Access Study Protocol

NCT02488681
View directory record Official record
Conditions
Bradycardia
Interventions
Micra Pacemaker Implant
Device
Lead sponsor
Medtronic
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 22, 2026, 8:40 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

NCT04481919
View directory record Official record
Conditions
Heart Failure, Acute Heart Failure
Interventions
Protocolized diuretic therapy
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
19 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational

SURPASS Impella 5.5 Study

NCT05100836
View directory record Official record
Conditions
Cardiogenic Shock, Acute Decompensated Heart Failure
Interventions
Impella 5.5
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

NCT02819011
View directory record Official record
Conditions
Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
Interventions
MBB AFO, Control
Device · Other
Lead sponsor
Bijan Najafi, PhD
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

NCT01896271
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
IL-2, Stereotactic Ablative Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT01326871
View directory record Official record
Conditions
Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
Interventions
Cisplatin, Gemcitabine, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Tucson, Arizona • Orlando, Florida • Stuart, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational

Inflammatory Cytokine Variations in Traumatic Injury Responses

NCT00593892
View directory record Official record
Conditions
Traumatic Complication of Injury
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 22, 2026, 8:40 AM EDT
Available No phase listed Expanded access

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

NCT03015844
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
131-I-meta-iodobenzylguanidine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
365 Days to 29 Years
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

NCT01702064
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Nilotinib, Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated No phase listed Observational

Impact of Tachycardia on Outcome After Subarachnoid Hemorrhage (SAH)

NCT01585311
View directory record Official record
Conditions
Subarachnoid Hemorrhage (SAH), Tachycardia
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-Op Lidocaine Patch

NCT03500211
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Lidoderm 5 % Topical Patch, Sham Topical Patch
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus

NCT05490511
View directory record Official record
Conditions
CBD, Transplant Complication, Kidney Disease, Chronic
Interventions
Tacrolimus single dose, Epidiolex single dose, Epidiolex steady-state and tacrolimus single dose
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 1 Interventional

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

NCT02973399
View directory record Official record
Conditions
Cancer
Interventions
SNX-5422 plus ibrutinib
Drug
Lead sponsor
Esanex Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 1 Interventional

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

NCT00852709
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Interventions
Clofarabine, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational

Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients

NCT03300739
View directory record Official record
Conditions
COPD Exacerbation, Copd
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

NCT00375219
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

NCT04791228
View directory record Official record
Conditions
Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 22, 2026, 8:40 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis

NCT00004300
View directory record Official record
Conditions
Stereotyped Behavior, Mental Retardation
Interventions
bromocriptine, sertraline hydrochloride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Morganton, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 22, 2026, 8:40 AM EDT